Nuvectis Pharma, INC

Nuvectis Pharma reported Q2 2026 results, highlighting the in-licensing of two promising drug candidates, the first global approval for ciprocopan in China, and a successful $115 million follow-on offering.

Nuvectis Pharma announced the pricing of its public offering of common stock, raising approximately $100 million in gross proceeds.

Nuvectis Pharma, Inc. has suspended its at-the-market stock offering and reduced the maximum amount available for future sales to $5 million.

Nuvectis Pharma reported Q1 2026 results, highlighting continued patient enrollment in its NXP900 Phase 1b trial and preclinical data supporting combination therapy.

Nuvectis Pharma, Inc. announced its financial results for the year ended December 31, 2025, highlighting progress in its NXP900 clinical development program and a strengthened cash position.

Nuvectis Pharma reports Q3 2025 financial results and business highlights, including the initiation of its NXP900 Phase 1b program and a strong cash position.

Nuvectis Pharma, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development, significant operating losses, and a substantial capital raise in July 2026.

Nuvectis Pharma reported its Q1 2026 results, showing continued operating losses and net losses, with cash reserves sufficient for at least 12 months, while advancing its NXP900 clinical development.

Nuvectis Pharma reported increased losses in Q3 2025, driven by higher R&D and G&A expenses, while advancing its NXP900 clinical program and discontinuing NXP800 development in ovarian cancer.

Nuvectis Pharma reported increased net losses in Q2 2025 due to higher research and development and general and administrative expenses, despite a significant capital raise.

Nuvectis Pharma reports its Q1 2025 financial results, emphasizing ongoing clinical development of NXP800 and NXP900 and its current cash position.

Nuvectis Pharma, a biopharmaceutical company, released its financial results for the third quarter of 2024, highlighting ongoing clinical development of its precision medicine candidates.

Nuvectis Pharma's latest 10-K filing highlights positive Phase 1a results for its lead oncology drug candidate NXP900, while reporting continued significant operating losses and the cessation of NXP800 clinical development.

Nuvectis Pharma reports its 2024 financial results, highlighting ongoing clinical trials for NXP800 and NXP900 and a recent public offering to bolster its financial position.

Nuvectis Pharma's 2023 10-K filing outlines the company's financial status, clinical development programs for NXP800 and NXP900, and associated risks.

Marlio Charles Mosseri, a director at Nuvectis Pharma, Inc., reported the acquisition of 50,000 common shares.

Nuvectis Pharma CEO Ron Bentsur acquired 12,500 shares of common stock for $250,000 in a public offering on June 30, 2026.

Director Kenneth Hoberman acquired 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Director James F. Oliviero III was granted 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Director Juan Sanchez acquired 35,000 shares of restricted common stock in Nuvectis Pharma, Inc. as part of a compensation grant.

Director Matthew L. Kaplan was granted 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

Nuvectis Pharma's upcoming annual meeting on June 13, 2024, will include voting on the election of directors and ratification of the company's accounting firm.

Nuvectis Pharma will hold its annual stockholders meeting virtually on June 12, 2025, to elect a director and ratify the appointment of its accounting firm.

Nuvectis Pharma's upcoming annual meeting on June 13, 2024, will include voting on the election of directors and ratification of the company's accounting firm.

Nuvectis Pharma will hold its Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent auditor.